Spots Global Cancer Trial Database for nintedanib
Every month we try and update this database with for nintedanib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer | NCT01583322 | Ovarian Cancer | vargatef placebo | 18 Years - | ARCAGY/ GINECO GROUP | |
| Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer | NCT02225405 | Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Cisplatin Docetaxel Laboratory Biom... Nintedanib | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma | NCT02308553 | Cutaneous Malig... | Nintedanib Nintedanib-Plac... Paclitaxel | 18 Years - | University Hospital, Essen | |
| Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT02399215 | Carcinoid Tumor Metastatic Carc... Neuroendocrine ... | Laboratory Biom... Nintedanib Pharmacological... Quality-of-Life... | 18 Years - | Roswell Park Cancer Institute | |
| Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] | NCT02780700 | Colorectal Neop... | Nintedanib Capecitabine | 18 Years - | Boehringer Ingelheim | |
| Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma | NCT02808247 | Sarcoma, Soft T... | Nintedanib Ifosfamide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | NCT01948141 | Recurrent Non-s... Squamous Cell L... Stage III Non-s... Stage IV Non-sm... | nintedanib | 18 Years - | Roswell Park Cancer Institute | |
| Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer | NCT02225405 | Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Cisplatin Docetaxel Laboratory Biom... Nintedanib | 18 Years - | M.D. Anderson Cancer Center | |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | NCT02863055 | Malignant Pleur... | Nintedanib Placebo | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Trial Of Pembrolizumab And Nintedanib | NCT02856425 | Patients With A... | Nintedanib Pembrolizumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | NCT01225887 | Endometrial Ade... Endometrial Cle... Endometrial Muc... Endometrial Ser... Endometrial Squ... Endometrial Tra... Endometrial Und... Malignant Uteri... Recurrent Uteri... | Nintedanib | 18 Years - | GOG Foundation | |
| Nintedanib(BIBF1120) in Thyroid Cancer | NCT01788982 | Medullary Thyro... Differentiated ... | Nintedanib Placebo | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | NCT02568449 | Recurrent Pleur... Stage IV Pleura... | Nintedanib | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Nintedanib in Patients With Advanced Esophagogastric Cancer | NCT02234596 | Esophagogastric... | Nintedanib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | NCT02902484 | Cancer of Pancr... | Nintedanib | 18 Years - | University of Texas Southwestern Medical Center | |
| Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | NCT02902484 | Cancer of Pancr... | Nintedanib | 18 Years - | University of Texas Southwestern Medical Center | |
| LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma | NCT03287947 | Appendix Cancer | nintedanib | 18 Years - | Wake Forest University Health Sciences | |
| ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer | NCT02009579 | Uterine Cervica... | Nintedanib Placebo | 18 Years - | Belgian Gynaecological Oncology Group | |
| Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma | NCT02668393 | Carcinoma, Non-... | Docetaxel Nintedanib Nintedanib Nintedanib Nintedanib | 18 Years - | Boehringer Ingelheim | |
| Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens | NCT01948141 | Recurrent Non-s... Squamous Cell L... Stage III Non-s... Stage IV Non-sm... | nintedanib | 18 Years - | Roswell Park Cancer Institute | |
| A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | NCT03062943 | Lymphangioleiom... | Nintedanib | 18 Years - | IRCCS Multimedica | |
| A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | NCT02152059 | Small Cell Lung... Platinum-sensit... | BIBF1120 | 18 Years - | AHS Cancer Control Alberta | |
| Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis | NCT02496585 | Lung Cancer Lung Metastases | Nintedanib Prednisone Placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | NCT03377023 | Non Small Cell ... Lung Cancer, No... Non Small Cell ... | Nivolumab Ipilimumab Nintedanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy | NCT02300298 | Carcinoma, Non-... | Nintedanib Docetaxel | 20 Years - | Boehringer Ingelheim | |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | NCT02863055 | Malignant Pleur... | Nintedanib Placebo | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | NCT02866370 | Ovarian Clear C... Endometrial Cle... | Nintedanib Paclitaxel Pegylated Lipos... Topotecan Carboplatin Doxorubicin | 18 Years - | NHS Greater Glasgow and Clyde | |
| Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | NCT02299141 | Carcinoma, Non-... Non-Small Cell ... Nonsmall Cell L... | Nintedanib | 18 Years - | Washington University School of Medicine | |
| Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer | NCT02751385 | Carcinoma, Non-... | Microgynon Nintedanib | 18 Years - | Boehringer Ingelheim | |
| A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) | NCT03062943 | Lymphangioleiom... | Nintedanib | 18 Years - | IRCCS Multimedica | |
| Nintedanib (BIBF 1120) in Mesothelioma | NCT01907100 | Mesothelioma | Nintedanib Pemetrexed Cisplatin Cisplatin Pemetrexed Placebo | 18 Years - | Boehringer Ingelheim | |
| Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) | NCT02856867 | Esophagogastric... Metastatic Dise... No Previous Che... | Nintedanib Fluorouracil Leucovorin Oxaliplatin Placebo | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | NCT02866370 | Ovarian Clear C... Endometrial Cle... | Nintedanib Paclitaxel Pegylated Lipos... Topotecan Carboplatin Doxorubicin | 18 Years - | NHS Greater Glasgow and Clyde | |
| Nintedanib in Patients With Advanced Esophagogastric Cancer | NCT02234596 | Esophagogastric... | Nintedanib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer | NCT01583322 | Ovarian Cancer | vargatef placebo | 18 Years - | ARCAGY/ GINECO GROUP | |
| Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer | NCT01658462 | Breast Cancer | Docetaxel Nintedanib Docetaxel: incr... | 18 Years - | Centre Oscar Lambret | |
| Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | NCT02568449 | Recurrent Pleur... Stage IV Pleura... | Nintedanib | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | NCT02152059 | Small Cell Lung... Platinum-sensit... | BIBF1120 | 18 Years - | AHS Cancer Control Alberta |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
